What is Gonadorelin?
The short answer
Gonadorelin is a lab-made form of the hormone that tells the body to make sex hormones.
What it is
Native GnRH; pulses stimulate LH and FSH release.
What people look into
Testosterone
- 5 sources
- Status as of
- How we source
- Ellum doesn't sell peptides.
Get updates on Gonadorelin
What it is
- Type
- GnRH (peptide)
- Also known as
- factrel, lutrepulse, gnrh, gonadorelin acetate
- How it works
- Native GnRH; pulses stimulate LH and FSH release.
Regulatory status
FDA-approved, discontinued How we label status
FDA status (as of October 4, 2026): Approved for people as Factrel in 1982 and Lutrepulse in 1989. Both have since been discontinued. The federal drug label site DailyMed lists gonadorelin only in drugs for animals
- Federal (FDA)
- Approved for people as Factrel in 1982 and Lutrepulse in 1989. Both have since been discontinued. The federal drug label site DailyMed lists gonadorelin only in drugs for animals
- 503A compounding
- No 503A category; 503B Category 1 as approved-drug component (as of March 21, 2025)
- WADA 2026
- S2.2.1 (males)
Timeline
Scroll sideways to see all columns.
Timeline table
| Date | What happened | Source |
|---|---|---|
| FDA final rule amends the animal drug regulations to reflect approval of an abbreviated application for a gonadorelin diacetate tetrahydrate solution for dairy cattle. | Federal Register, event of July 19, 1996, on federalregister.gov | |
| FDA final rule amends the animal drug regulations to reflect approval of a second abbreviated application for a gonadorelin diacetate tetrahydrate solution for dairy cattle. | Federal Register, event of November 13, 2002, on federalregister.gov |
US enforcement actions
1 US enforcement action, in 2026.
Actions by US federal and state agencies whose documents name Gonadorelin. Each row links to the government's own document.
Scroll sideways to see all columns.
US enforcement actions table
| Date | Agency | Action | Document |
|---|---|---|---|
| FDA | Warning letter | FDA document, warning letter, June 17, 2026, on fda.gov |
References
Sources as of October 4, 2026
- Drugs@FDA: www.accessdata.fda.gov/scripts/cder/daf/index.cfm (1 of 2)
- Drugs@FDA: www.accessdata.fda.gov/scripts/cder/daf/index.cfm (2 of 2)
- FDA: www.fda.gov/media/94164/download
- FDA warning letter, June 17, 2026
- WADA: www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf